Lifeboat Foundation

Novo Nordisk’s recent growth renaissance has arrived thanks in no small part to semaglutide—the GLP-1 molecule behind the company’s leading marketed trio of Ozempic, Rybelsus and Wegovy.

These days, much of the semaglutide hype surrounds Ozempic’s domination in diabetes, plus Wegovy’s potential to stir the slumbering giant that is the global obesity market. But even as the molecule’s metabolic empire prospers, Novo Nordisk isn’t letting its GLP-1 stay in its comfort zone. Novo is also pitting the drug against a pair of elusive targets: nonalcoholic steatohepatitis (NASH) and Alzheimer’s disease.

And while CEO Lars Fruergaard Jørgensen is quick to admit the company’s ambitions in these new diseases are among Novo’s “most risky” R&D endeavors, the payoff for patients could be “tremendous,” he said during a recent interview at Novo Nordisk’s headquarters in Plainsboro, New Jersey.

“Intrinsically unstable, a wormhole would need ‘stuff’ with repulsive gravity to hold open each mouth, and the energy equivalent to that emitted by an appreciable fraction of the stars in a galaxy,” reads Science Focus’ story. The idea would be that “if ETs have created a network of wormholes, it might be detectable by gravitational microlensing.”

That technique has been used in the past to detect thousands of distant exoplanets and stars by detecting how they bend light. Whether it could be used to detect wormholes, to be clear, is an open question.

Fortunately, spotting wormholes isn’t our only shot at detecting life elsewhere in the universe. Science Focus also pointed to the search for theoretical megastructures that harness the energy of a star by fully enclosing it, or atmospheric chemicals linked to human pollution, or extremely thin reflective spacecraft called light sails, any of which could theoretically lead us to discover an extraterrestrial civilization.

Pioneering scientists think we should start looking for extraterrestrials in a whole new way: by seeking out alien technology.

The search for alien life is ramping up. But what if, instead of searching for signs of biology, we looked for something more familiar: an extraterrestrial civilisation.

We speak to astrobiologist and extraterrestrial researcher Dr Douglas Vakoch about transmitting messages into the cosmos in the hope of finding intelligent extraterrestrial life.

Facebook CEO Mark Zuckerberg might be getting excited about the metaverse, but the idea is nothing new.

But with such a rapid expansion into this new virtual world, will it be safe, regulated and, is it something we should fear or accept with open arms?

We talk to David Reid, a Professor of AI and spatial computing at Liverpool Hope University to see what to expect from the future of the metaverse.

There’s a few definitions. You can think of it from a technological viewpoint, where it’s simply the successor of the internet. Computers once took up big rooms, but they’ve shrunk until we got things like pocket-sized smartphones that you constantly interact with. The metaverse takes this a step further, making the actual environment you interact with virtual, removing the interface of computers completely.

The promising results led to improved not only cognitive function but also brain connectivity.

An Inserm team at the Lille Neuroscience & Cognition laboratory is working with scientists at Lausanne University Hospital to evaluate the effectiveness of GnRH injection therapy in enhancing cognitive functions in a small group of Down syndrome patients, according to a press release published on Eurekalert.

Down syndrome is the most common chromosomal condition in the United States. According to the Centers for Disease Control and Prevention, about one in every 6,000 babies born in the U.S. has Down syndrome. It causes various symptoms, such as deterioration in cognitive capacity.

Negative symptoms are complex psychopathology. Although evidence generally supported the NIMH five consensus domains, research seldom examined measurement invariance of this model, and domain-specific correspondence across multiple scales. This study aimed to examine the interrelationship between negative symptom domains captured by different rating scales, and to examine the domain-specific correspondence across multiple scales. We administered the Brief Negative Symptom Scale (BNSS), the Self-evaluation of Negative Symptoms (SNS), and the Scale for Assessment of Negative Symptoms (SANS) to 204 individuals with schizophrenia. We used network analysis to examine the interrelationship between negative symptom domains.